



SoonerCare Fax Blast

April 6, 2009

SUBJECT: Stimulants - ADHD

Dear Provider:

This update is part of an ongoing series featuring SoonerCare medication prior authorization (PA) criteria. Each update will include current information on a different therapeutic category.

- PA information for all therapeutic categories is available at www.okhca.org/providers/rx/pa.
- PA forms are available at www.okhca.org/rx-forms.

Tier-1	Tier-2	Tier 3
amphetamine salt combo (Adderall [®])	amphetamine salt combo (Adderall [®] XR)	armodafinil (Nuvigil [®])
dexmethylphenidate (Focalin [®] , Focalin [®] XR)	atomoxetine (Strattera [®])	dextroamphetamine (Dexedrine [®] , Dextrostat [®])
lisdexamfetamine (Vyvanse [®])	methylphenidate ER (Metadate [®] CD)	methamphetamine (Desoxyn [®])
methylphenidate IR (Ritalin [®] , Methylin [®])	methylphenidate ER (Metadate [®] ER)	methylphenidate patch (Daytrana [™])
methylphenidate ER (Concerta [®])	methylphenidate ER (Ritalin [®] LA)	modafinil (Provigil [®])
methylphenidate SR (Ritalin [®] SR)		

Stimulant / ADHD Prior Authorization

Tier-1 medications are available without prior authorization for members under age 21.

Prior authorization is required for all stimulants for adults age 21 and older.

Tier-2 authorization requires:

1. Documented trial of one longer-acting Tier-1 medication within the last 30 days with inadequate results, and
2. Diagnosis of ADHD or Narcolepsy

Tier 3 authorization requires:

1. Documented trial of two long-acting Tier-1 or Tier-2 medications with inadequate results (both trials within the last 60 days), and
2. Diagnosis of ADHD or Narcolepsy.

Other criteria for this category:

- No concurrent use of multiple products from this category, i.e. Strattera + Stimulant, Methylphenidate + Amphetamine
- Immediate release products are available on Tier-1 without a prior authorization, but are not considered an adequate trial. Please consider non-immediate release formulations whenever appropriate.
- BID dosing of products indicated for once daily dosing is not covered. If additional doses are needed, the immediate release formulations are available without prior authorization for members under 21 years of age.
- Dose not to exceed 1.5 times the FDA approved maximum.